FeesSafety
Pluang+

Pfizer shows strong new drug growth and backs a 6% dividend despite patent challenges.

Market News
21 Nov 2026, 00:15 WIB
The Motley Fool
View Source
Bullish
Pfizer shows strong new drug growth and backs a 6% dividend despite patent challenges.

Pfizer is navigating typical pharmaceutical challenges like patent expirations on key drugs but is offsetting revenue losses with a 32% rise in sales from new and acquired products. The company maintains a strong financial position with $1.8 billion in cash and $12.4 billion in short-term investments, supporting its business and a high 6.1% dividend yield. Despite investor skepticism reflected in lower valuation ratios, Pfizer's management is committed to sustaining and growing its dividend, backed by solid cash flow and reserves. These factors make Pfizer an attractive stock for dividend-focused investors, even amid industry headwinds.

Pfizer's stock trades at USD 27.42 on Pluang, showing a slight decline of 0.44% in the last day. The dividend yield remains attractive at 6.25%, with most Pluang users currently selling the stock. These figures are current as of Nov 21, 2026 05:11 WIB.

More News (PFE)

Five high-yield dividend stocks under $50 offer retirees reliable income across diverse sectors.

Five high-yield dividend stocks under $50 offer retirees reliable income across diverse sectors.

Five dividend stocks trading under $50 per share—Verizon, Kinder Morgan, Pfizer, KeyCorp, and NNN REIT—offer retirees attractive yields backed by strong cash flow and earnings coverage. Verizon leads with a 6.07% yield supported by rising free cash f...

Bullish
11 hours ago
Three dividend stocks yield more than the 1-year Treasury bill, offering higher income with some risk.

Three dividend stocks yield more than the 1-year Treasury bill, offering higher income with some risk.

Pfizer, British American Tobacco, and Enbridge offer dividend yields of 6.25%, 5.81%, and 5.91% respectively, all exceeding the 4.59% yield of the 1-year Treasury bill as of November 2026. These stocks provide income from diverse sectors—healthcare, ...

Bullish
13 hours ago
Pfizer set to pay its 352nd consecutive dividend on Dec 7, 2026, despite potential challenges ahead.

Pfizer set to pay its 352nd consecutive dividend on Dec 7, 2026, despite potential challenges ahead.

Pfizer will pay its 352nd consecutive quarterly dividend on December 7, 2026, maintaining a strong track record for investors. The company faces challenges like a patent cliff, costly acquisitions, and clinical setbacks that could threaten this strea...

Company Fundamentals
Neutral
1 day ago
Pfizer set to pay its 352nd consecutive dividend on Dec 7, 2026, despite patent cliff risks.

Pfizer set to pay its 352nd consecutive dividend on Dec 7, 2026, despite patent cliff risks.

Pfizer will pay its 352nd consecutive quarterly dividend on December 7, 2026, maintaining a long-standing payout streak. Although the company faces challenges like a patent cliff, costly acquisitions, and clinical trial setbacks, it currently has eno...

Company Fundamentals
Neutral
1 day ago
Pfizer's strong Q3 and raised 2026 EPS guidance ease patent expiration fears, keeping it a Buy for investors.

Pfizer's strong Q3 and raised 2026 EPS guidance ease patent expiration fears, keeping it a Buy for investors.

Pfizer Inc. delivered strong Q3 results driven by its oncology portfolio, Eliquis, and tafamidis franchise, with Eliquis revenue growing 25.2% year-over-year to about $2.5 billion. Despite concerns about an upcoming patent expiration cycle lasting ar...

Company Fundamentals
Bullish
2 days ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App